KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Cash from Financing Activities for 7 consecutive years, with -$299.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 16.14% to -$299.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Dec 2025, down 428.39% year-over-year, with the annual reading at -$1.2 billion for FY2025, 428.39% down from the prior year.
  • Cash from Financing Activities hit -$299.6 million in Q4 2025 for Royalty Pharma, down from $562.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.2 billion in Q2 2024 to a low of -$1.4 billion in Q3 2023.
  • Historically, Cash from Financing Activities has averaged -$176.7 million across 5 years, with a median of -$229.2 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 490.86% in 2023 and later skyrocketed 433.32% in 2024.
  • Year by year, Cash from Financing Activities stood at -$198.1 million in 2021, then plummeted by 34.07% to -$265.6 million in 2022, then rose by 12.67% to -$231.9 million in 2023, then decreased by 11.24% to -$258.0 million in 2024, then fell by 16.14% to -$299.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for RPRX at -$299.6 million in Q4 2025, $562.7 million in Q3 2025, and -$507.8 million in Q2 2025.